• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

COVID-19: first set of specific healthcare recommendations issued for people living with Chagas disease

People living with this neglected disease are facing an increased risk from COVID-19

Home > Press releases

COVID-19: first set of specific healthcare recommendations issued for people living with Chagas disease

People living with this neglected disease are facing an increased risk from COVID-19

Healthcare worker in mask looks after Chagas patient
Geneva/Rio de Janeiro — 13 Oct 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español
    • Português

A group of experts has published the first set of COVID-19-related healthcare recommendations for the millions of people living with Chagas disease, a neglected tropical disease. Six million people are affected by Chagas, a ‘forgotten’ disease known to impact the heart and other organs; they faced significant challenges in accessing healthcare even before the pandemic, and they are now facing an increased risk from COVID-19.

Because Chagas causes cardiac, gastrointestinal, and other complications that could increase susceptibility to COVID-19, a group of experts on Chagas and heart-related diseases from all over the world joined together to provide the best available guidance for healthcare providers. Their recommendations, which include testing and possible drug interactions, were published on 13 October in Global Heart.

‘COVID-19 disproportionately affects the most vulnerable either socioeconomically, due to age, or underlying health conditions; patients now face a double or triple plight as many are already at the social margins and are suffering from neglected tropical diseases such as Chagas disease that poses a medical challenge that deserves our attention and resources as much as any other,’ said  Fausto Pinto, President-Elect of the World Heart Federation and one of the paper’s authors.

Caused by the parasite Trypanosoma cruzi, Chagas can take a multi-functional toll on the digestive system, the nervous system, and the heart. More than one million people suffer from chronic Chagas cardiomyopathy that diminishes the blood-pumping function of the heart, leading to heart failure, and often causing irreversible damage. Endemic to Latin America, the disease has a long asymptomatic phase, with many people unaware they are infected.

Diseases such as Chagas were already neglected before the pandemic; now, diversion of resources to fight the pandemic, strains on healthcare facilities, patient concerns about contracting COVID-19 when visiting clinics, and limited understanding of the interactions between diseases and their drug treatments are posing new challenges for confronting Chagas and other neglected diseases.

‘The current situation further exposes the underlying inequalities in access to care and calls for better healthcare solutions for all patients. The pandemic affects treatment provision to people with acute or chronic Chagas disease, and patients suffering from cardiomyopathy require special consideration because of COVID-19’s potential impact on the heart. The recommendations for healthcare workers outline ways to keep all Chagas patients protected and also to optimize COVID-19 care for Chagas patients directly affected by COVID-19,’ said Sergio Sosa-Estani, Head of Chagas Clinical Programme at DNDi and also one of the paper’s authors.

In both chronic Chagas cardiomyopathy and COVID-19, an inflammatory immune response and frequent co-morbidities increase the risk factors in patients. Questions to be studied further include the links between inflammation due to COVID-19 and due to Chagas disease, and the potential of the immune response in COVID-19 to worsen or reactivate Chagas disease. Based on currently available data, this new and important paper documents guidance as well as known information for different drug applications and interactions across both diseases. Also included are recommendations for screening and testing for people with different manifestations of Chagas disease, during pregnancy, and among those with compromised immune systems.

COVID-19 and Chagas disease share more than medical interactions and biological processes: both diseases affect some of the most vulnerable populations and raise urgent questions about accessible, affordable healthcare for everyone.

In addition to outlining detailed medical approaches and recommendations for Chagas disease patients with COVID-19, the authors of the paper therefore call for concerted, sustained action to address neglected diseases. By highlighting the gaps and needs in understanding the interaction between COVID-19 and Chagas disease, the authors hope to stimulate further research and public health investment and ultimately to bring out of the shadows diseases that have been ignored for too long.

Background on published paper

On 30 March 2020 the Inter-American Society of Cardiology (IASC) and World Heart Federation published a Roadmap on Chagas Disease with a comprehensive overview of Chagas disease and steps for improving healthcare access. In April 2020, the Drugs for Neglected Diseases initiative’s Chagas Research Platform reconvened some members of the Chagas disease roadmap writing group and other experts, including several members of the Chagas Coalition that has created a Q&A resource, to explore the impacts of COVID-19 on Chagas patients. Some members of the writing group have been on the frontlines of the pandemic, administering treatment or exploring new ones.

About the World Heart Federation

The World Heart Federation (WHF) unites the cardiovascular community and drives the agenda to reduce the global burden of cardiovascular disease and help people live longer, healthier lives. Together with our Members, we are working to end needless deaths and build global commitment for improved cardiovascular health at the global, regional, national and community levels. We believe in a world where heart health for everyone is a fundamental human right.

To learn more, visit www.worldheart.org

About DNDi

The Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit, patient-oriented research and development organization working to deliver safe, effective, and accessible treatments for millions of people living in vulnerable conditions and affected by neglected diseases, notably Chagas disease, leishmaniasis, sleeping sickness, paediatric HIV, hepatitis C, filarial infections, and mycetoma.

Media Contacts

Mihela Kralj, Communications Manager, WHF, mihela.kralj@worldheart.org

Marcela Dobarro, Regional Communications Manager, DNDi, mdobarro@dndi.org

Photo credit: Ana Ferreira-DNDi

COVID-19 Chagas disease

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
30 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo